Evelyn Partners Asset Management Ltd Increases Stake in Sanofi $SNY

Evelyn Partners Asset Management Ltd lifted its position in Sanofi (NASDAQ:SNY) by 24.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,904 shares of the company’s stock after acquiring an additional 1,754 shares during the quarter. Evelyn Partners Asset Management Ltd’s holdings in Sanofi were worth $430,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Ameritas Advisory Services LLC bought a new stake in Sanofi in the second quarter worth about $28,000. Accent Capital Management LLC bought a new position in shares of Sanofi during the first quarter valued at approximately $29,000. Eastern Bank raised its holdings in shares of Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after buying an additional 300 shares during the period. Banque Transatlantique SA bought a new stake in shares of Sanofi during the 1st quarter worth approximately $33,000. Finally, Brentview Investment Management LLC bought a new stake in shares of Sanofi during the 1st quarter worth approximately $42,000. 14.03% of the stock is currently owned by institutional investors.

Sanofi Stock Up 1.5%

NASDAQ:SNY opened at $49.63 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The company has a 50-day moving average of $49.29 and a 200 day moving average of $49.31. The firm has a market cap of $121.87 billion, a PE ratio of 11.62, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business had revenue of $14.53 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same quarter in the previous year, the business posted $2.25 EPS. The company’s quarterly revenue was down 7.5% compared to the same quarter last year. As a group, research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Tuesday, November 11th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $56.00 to $58.00 in a report on Monday, September 8th. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Sanofi has an average rating of “Buy” and a consensus target price of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.